Market Cap | 38.58M | P/E | - | EPS this Y | 39.00% | Ern Qtrly Grth | - |
Income | -87.68M | Forward P/E | -0.78 | EPS next Y | 1.20% | 50D Avg Chg | -12.00% |
Sales | 15.53M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -24.00% |
Dividend | N/A | Price/Book | 0.46 | EPS next 5Y | - | 52W High Chg | -63.00% |
Recommedations | 2.50 | Quick Ratio | 5.68 | Shares Outstanding | 72.58M | 52W Low Chg | 7.00% |
Insider Own | 20.39% | ROA | -36.64% | Shares Float | 37.90M | Beta | 2.34 |
Inst Own | 60.53% | ROE | -89.48% | Shares Shorted/Prior | 657.21K/365.60K | Price | 0.90 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 219,895 | Target Price | 4.00 |
Oper. Margin | -942.67% | Earnings Date | May 7 | Volume | 84,169 | Change | 2.09% |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Piper Sandler | Overweight | Jan 17, 23 |
Piper Sandler | Overweight | Jan 6, 23 |
Jefferies | Buy | Jan 6, 23 |
SVB Leerink | Market Perform | Nov 3, 22 |
SVB Leerink | Market Perform | May 5, 22 |
SVB Leerink | Outperform | Mar 23, 22 |
Piper Sandler | Neutral | Mar 23, 22 |
Piper Sandler | Overweight | Mar 11, 22 |
SVB Leerink | Outperform | Mar 11, 22 |